Navigating Commercial Logistics: Key Considerations For Emerging Cell And Gene Therapy Manufacturers

Commercializing cell and gene therapies (CGTs) presents a unique set of logistical challenges that demand precision and a patient-first mindset. From maintaining strict temperature controls to managing individualized, patient-specific products, every stage of the supply chain requires careful planning. Emerging manufacturers must build a robust logistics strategy that can scale with demand and withstand inevitable disruptions.

This involves integrating digital infrastructure for real-time visibility, building redundancy into critical components, and planning for future global expansion from the outset. Early collaboration with experienced partners is vital to ensure these complex therapies are delivered reliably, compliantly, and on time. To learn more about how to prepare for a successful launch, read the full article.